Document Detail

Hormone replacement therapy and ovarian cancer risk: a meta-analysis.
MedLine Citation:
PMID:  18221779     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Epidemiologic findings are inconsistent concerning the risk for ovarian cancer associated with hormone replacement therapy (HRT). We conducted a meta-analysis to summarize the available evidence from observational studies to examine this relation. METHODS: We searched PUBMED and MEDLINE for relevant studies that were published from January 1, 1966, through May 1, 2007. Study-specific risk estimates were pooled by the use of a random-effects model. RESULTS: Eight cohort (including 4715 cases and 1,555,374 participants) and 19 case-control studies (involving 8240 cases and 20,996 controls) were included. We found a summary relative risk (RR) of 1.24 (95% confidence interval [CI] 1.15-1.34) from cohort studies and a summary odds ratio [OR] of 1.19 (95%CI 1.02-1.40) from case-control studies for ever HRT use. However, the risk estimates of case-control studies might be upwardly biased. Summary risk estimates of four cohort and six case-control studies that distinguished estrogen replacement treatment (ERT) and estrogen-progestin replacement treatment (EPRT) from HRT both indicated that association was stronger among ERT user than EPRT user. Based on data abstracted from six case-control studies, duration of HRT use was not significant. The summary risk estimates for less than 5 years, 6-10, and more than 10 years use were 1.02, 1.13, and 1.21, respectively and 95%CI for each estimate crossed 1.0. CONCLUSION: HRT use was associated with increased risk of ovarian cancer. These findings may expand the range of possible risks associated with HRT use. However, this positive association should also be considered in the context of HRT's other favorable effects on health.
Bo Zhou; Qingmin Sun; Rihong Cong; Haijuan Gu; Naping Tang; Li Yang; Bin Wang
Related Documents :
16354459 - Managing the menopause: british menopause society council consensus statement on hormon...
15869589 - Does the type of hormone replacement therapy influence the risk of deep vein thrombosis...
12888369 - Does hormone replacement therapy increase the frequency of breast atypical hyperplasia ...
18341679 - Clinically informative measures of the effect of drugs or other interventions.
12859699 - Acute intermittent porphyria in women: clinical expression, use and experience of exoge...
15590209 - Hormone replacement therapy in the menopause. structure and content of risk talk.
21060049 - Prospective study of common variants in the retinoic acid receptor-related orphan recep...
15358739 - Prediction of bone mineral density from vitamin d receptor polymorphisms is uncertain i...
18308039 - Project promis: peoria regional outpatient medical imaging study.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2008-01-24
Journal Detail:
Title:  Gynecologic oncology     Volume:  108     ISSN:  1095-6859     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-25     Completed Date:  2008-03-20     Revised Date:  2008-09-09    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  641-51     Citation Subset:  IM    
Department of Pharmacology, Nanjing Medical University, Jiangsu, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Estrogen Replacement Therapy / adverse effects*
Ovarian Neoplasms / epidemiology*,  etiology,  pathology
Risk Factors
Erratum In:
Gynecol Oncol. 2008 Sep;110(3):455

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Defining survivorship after high-grade aneurysmal subarachnoid hemorrhage.
Next Document:  Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of ...